Dear prospective partner,

Thank you for taking the time to read this document.

Restora is the flagship project of Aika Lab, a Gothenburg-based AI player. After months of research, we are launching this initiative to build a smart wearable device that finally enables hundreds of millions of orthopedic post-surgery patients worldwide to undergo clinical-grade recovery at home. We have already completed a comprehensive project foundation: eight core documents covering international competitive analysis, literature review, product PRD, preliminary design, procurement guide, visual system brief, two-phase commercialization strategy, and investor materials.

We recognize clearly: between a thoughtful research package and a real, medical-grade product reaching homes, hospitals, and regulatory approvals, there are four critical bridges — industrialization, scaled manufacturing, clinical certification, and market distribution. These are precisely the parts we hope to build together with you.

This document presents in full: the project background and global landscape, technical and product solution, business vision, feasibility analysis, and the partnership models we wish to explore together. If you are an enterprise or entrepreneur capable of advancing innovative medical / digital health products to market, we very much look forward to opening a deep dialogue with you.

—— The Aika Lab Project Team
May 2026 · Gothenburg, Sweden

Restora is the world's first wearable device that integrates four mainstream neuromodulation modalities — taVNS (transcutaneous auricular vagus nerve stimulation), NMES (neuromuscular electrical stimulation), PEMF (pulsed electromagnetic field), and LIPUS (low-intensity pulsed ultrasound) — into a single non-invasive product. Leveraging phone-driven algorithms with closed-loop sensing, it enables personalized, clinical-grade at-home recovery covering all core needs during the orthopedic recovery window: improved blood circulation, anti-inflammation, edema reduction, and accelerated bone healing.

• Company entity: Aika Lab (Gothenburg, Sweden) — project sponsor, carrying technology and platform assets
• Product / APP brand: Restora — patient and physician-facing product identity
• Sub-brands: Restora Recovery (consumer wellness) + Restora Medical (regulated medical device)
• Brand moat: trademark FTO clearance in progress, covering primary categories in CN / US / EU

Approximately 400 million fractures and orthopedic surgeries occur globally each year — including limb fractures, hip / knee replacements, spinal fusion, and sports injury reconstructions. During the critical 0–12 week post-op recovery window, patients commonly face a triple challenge:

• Uncontrolled inflammation: Fracture and surgical trauma trigger large surges in IL-6, TNF-α and other pro-inflammatory cytokines. Excessive inflammation suppresses osteoblast activity and is a leading cause of delayed healing.
• Microcirculation impairment: Cast / brace fixation and bed rest cause venous stasis and lymphatic drainage disruption, leading to local edema, hypoxia, and delayed tissue repair.
• Muscle atrophy and sympathetic dysregulation: 4–6 weeks of immobilization can reduce muscle cross-sectional area by 20–40% and trigger abnormal sympathetic activation — a key risk factor for Complex Regional Pain Syndrome (CRPS).

Take wrist fractures as an example: post-op CRPS incidence runs as high as 4–37% (depending on diagnostic criteria). Once it occurs, treatment costs rise by orders of magnitude over standard rehabilitation, with long-term impact on functional recovery and return to work.

Yet this 12-week recovery window is almost completely a service blind spot in today's healthcare systems: tertiary hospital orthopedic / rehabilitation departments are stretched thin, primary care cannot absorb the demand, home-based recovery lacks monitoring and personalized intervention, and patients are essentially disconnected from their physicians after discharge.

Neuromodulation, as a new "non-pharmacological" intervention category, is entering the medical mainstream at unprecedented speed. According to Precedence Research and other leading market research firms:

The orthopedic + rehabilitation sub-segment has not yet been independently quantified — signaling a major untapped market opportunity.

We systematically analyzed 12 major international players across 5 technology tracks and reached a clear conclusion: each existing product solves only one piece of the "recovery full picture," and no product worldwide simultaneously covers all four quadrants — blood flow + inflammation + edema + bone healing.

• SetPoint VNS received FDA approval in July 2025 as the first neuro-immune modulation therapy
• Theranica Nerivio received China NMPA approval in August 2025 — the first wearable neuromodulation product to enter the Chinese market
• PEMF, LIPUS, and NMES each have Level 1 meta-analysis support; the underlying mechanisms are systematically reviewed in Curr Osteoporos Rep 2024
• taVNS, micro-sensors, edge AI, and miniaturized PZT piezoelectric transducers all became consumer-grade accessible after 2024

Restora's architecture rests on a critical decision: signal generation, scheduling, and personalization algorithms all reside on the phone (leveraging Aika Lab's years of accumulated core algorithm capabilities), while peripherals only handle "transduction + execution + safety protection." The benefits: dramatically lower hardware barriers, fast iteration cycles, optimal BOM costs, and the cleanest regulatory path.

Three-Tier System Architecture

• Tier 1 · Phone Layer (Restora APP): Four-modality signal synthesis engine + adaptive algorithms + UX flows + physician prescription / patient home-use full lifecycle
• Tier 2 · NT-Hub Controller: Digital-to-analog conversion + 4 independent drive channels + three-layer safety guardrails + module identification (medical-grade IEC 60601-1 safety design)
• Tier 3 · Modular Peripherals: taVNS ear clip + NMES muscle patches + PEMF coil belt + LIPUS ultrasound probe + sensor patch (PPG / impedance / skin temperature / IMU)

Restora v1.0 is the world's first device to integrate four neuromodulation modalities within a single non-invasive wearable:

Moat 1: Technical Depth of Multi-Modality Fusion

Synchronizing four stimulation modalities requires thousands of hours of parameter tuning. Aika Lab already possesses full-stack signal generation capability across low-frequency electrical pulses, mid-frequency PEMF, acoustic / ultrasound, and high-frequency signals. New entrants starting from scratch would need at least 2 years to catch up.

Moat 2: Closed-Loop Sensing Algorithms

Existing RCTs all use "fixed parameter" protocols. Restora introduces real-time closed-loop feedback via PPG / impedance / EMG, allowing treatment intensity and duration to adapt to the patient's individual state. This "personalization algorithm" is a moat that cannot be obtained by hardware imitation alone.

Moat 3: First-Mover Clinical Evidence Advantage

Phase A / B / C three-stage RCTs will systematically establish the clinical evidence base for orthopedic indications. Every high-impact RCT publication adds 2–3 years for competitors to catch up. This is the truly durable moat in medical devices.

Restora avoids the traditional high-risk path of "regulatory approval before any market entry." Instead, we adopt the industry-proven "consumer first, medical next" two-phase strategy, validated by predecessors including Parasym, Oura, and Apple Watch.

The two-phase strategy is not merely sequential market entry — it is an organic "data flywheel":

• Real-world usage data from the consumer version naturally serves as the "real-world evidence" (RWE) control arm for the medical version's clinical research
• Hardware iteration learnings from the consumer version help the medical version avoid repeated mistakes
• Brand recognition built by the consumer version increases physician and patient acceptance of the medical version
• Cash flow from the consumer version supports the long-term clinical research and regulatory investment required for the medical version

4.4 Revenue & Growth Path

We have modeled revenue scenarios (detailed financial models are included in the formal business plan, available to partners after NDA execution):

• Phase 0 consumer version: ASP positioned at $130–$250 range, gross margin ~50–60%, first-year volume target on par with successful early-stage health / consumer electronics brands
• Phase 1 medical version: device + subscription model (one-time device + monthly algorithm subscription), with significantly higher ASP, gross margin influenced by hospital channels and insurance reimbursement
• Internationalization: US-first launch, leveraging the successful Theranica Nerivio path to enter China, with EU as a long-term market
• Growth curve: positive cash flow within 9–12 months of consumer version launch; medical version becomes long-term high-margin pillar business after approval

Core technology already in place. The Aika Lab team has accumulated years of algorithm and signal processing capability across the following key domains:

• Low-frequency electrical pulses (1–100 Hz, capable of driving TENS / NMES / taVNS)
• Mid-frequency pulsed electromagnetic fields (1–75 Hz block modulation, capable of driving PEMF coils)
• Acoustic / ultrasound (including the 1.5 MHz FDA-approved band, extensible to LIPUS bone healing)
• Phone-based algorithmic signal generation with Type-C output is mature

This means Restora's core technology does not need to be developed from scratch — we are engineering, productizing, and clinically validating capabilities already in hand.

Hardware barriers dramatically reduced. With the "phone-as-platform, peripherals-as-transducers" architecture, hardware itself doesn't need to handle complex signal synthesis. BOM is well-controlled (~$40 USD at 10K production volume), seamlessly integrating with mature contract manufacturers.

Clear prototyping path. A four-stage prototyping path (PoC → EVT → DVT → PVT) has been planned, reaching production-ready status in 9 months.

Solid evidence base. We completed a systematic literature review across PubMed and ClinicalTrials.gov, including 32 key RCTs and meta-analyses. Key findings:

• PEMF: Peng 2020 meta (22 RCTs, n=1,468) shows healing rate RR=1.22 [1.10–1.35]
• LIPUS: Schofer systematic review shows 82% nonunion healing rate (n=1,441)
• NMES: TKA / THR post-op meta shows 43% edema reduction (vs sham)
• taVNS: SetPoint RESET-RA RCT (n=242) shows ACR20 significantly superior to sham (35.2% vs 24.2%)

Three-stage RCT pathway. Phase A feasibility IIT (n≈40, 6 months) → Phase B factorial RCT (n≈80, 12 months) → Phase C pivotal RCT (n≈300, multi-center double-blind, 18 months, primary endpoint: ≥ 30% reduction in 12-week CRPS incidence).

Regulatory pathways for all three regions have been clarified, each with established precedents:

• Large market capacity: 400M annual fractures/surgeries × 30% complication rate = massive unmet need
• Clear cash flow path: consumer version launches and generates revenue within 6 months, avoiding the long "investment-only" death valley
• Validated willingness to pay: consumer payment habits for recovery devices already proven by brands like Theragun and Hyperice
• Brand inheritability: consumer brand assets transfer seamlessly to medical version, avoiding duplicate investment

We believe: a truly innovative medical / digital health product requires deep complementarity between "technology + industry" capabilities. Restora's core innovation stems from the Aika Lab team's years of algorithm and signal research. But for this innovation to actually reach hundreds of millions of patients, we need professional industrialization, scaled manufacturing, healthcare partnerships, and regulatory expertise — exactly the strengths of excellent industrial partners.

Therefore, we seek to build a strategic alliance with our partners, not a simple supplier relationship. Both sides should align on equity / governance / profit sharing / IP / brand and other key issues, jointly driving Restora to become a flagship product in the global orthopedic rehabilitation landscape.

• Option A · Joint Venture: Both sides co-invest in a new entity, with technology and industrial resources mapped to equity stakes
• Option B · Strategic Equity + Technology License: Partner takes strategic equity in Aika Lab while receiving Restora technology license
• Option C · Project Consortium: Sign joint development agreement on project basis, advancing in phases
• Option D · Regional Agency + Joint Operation: Partner takes exclusive rights for specific regions (e.g., Mainland China) with full local execution

The specific structure will be jointly determined during formal business negotiations after initial alignment of intent.

As a demonstration of our commitment to potential partners, we have completed a comprehensive project foundation package before extending this invitation. The following eight core documents are available for full disclosure to partners after NDA execution:

• Enterprises with established medical device / health consumer goods supply chains: mature CM resources, QC systems, regulatory experience
• Enterprises or individuals with hospital / rehabilitation channel networks: able to drive adoption in tertiary orthopedic / rehab departments
• Industrial partners familiar with FDA 510(k) / NMPA Class II / CE-MDR registration processes
• Enterprises with consumer medical / digital health brand operation capabilities: e-commerce + DTC + offline channels
• Industrial capital with intent to enter the neuromodulation / smart rehabilitation space
• Serial entrepreneurs with vision and execution: willing to treat "industrial execution" as their core mission

• Strategic vision: understands the long-term value of the "consumer fuels medical" two-phase strategy, not just short-term returns
• Execution capability: real experience driving products from prototype to mass production, sales, and hospital adoption
• Industrial resources: deep accumulation in at least one of manufacturing, sales, medical channels, or regulatory
• Collaboration willingness: willing to work deeply with the technical team to polish the product, not treating the project as simple CM or distribution business
• Long-termism: understands medical devices require 24–36 month development cycles, willing to engage as a "long-term partner"

• A "full-stack" project with completed foundation research, technology reserves, and brand strategy — dramatically reducing front-loaded execution risks
• Globally first-mover positioning in "non-invasive × four-modality × orthopedic recovery" — a 5–8 year market window
• Based on the "consumer fuels medical" two-phase strategy — cash flow within 9 months, no long waiting period
• Synchronized regulatory pathways in CN / US / EU — natural internationalization potential
• A core technical team with years of accumulated neuromodulation algorithm expertise

• Step 1 · Initial communication — phone / video meeting to understand each side's basics and intent (1–2 weeks)
• Step 2 · Mutual NDA — after signing, we provide full disclosure of the eight foundation documents to the partner (1 week)
• Step 3 · On-site exchange — partner visits our lab and prototypes; we learn the partner's industrial capabilities (2 weeks)
• Step 4 · Term sheet negotiation — discuss partnership structure, equity / profit sharing, IP, brand use, responsibility split, and other core issues (2–4 weeks)
• Step 5 · Formal agreement — depending on alignment: LOI (Letter of Intent) → MoU (Memorandum of Understanding) → formal partnership agreement
• Step 6 · Joint kickoff — establish joint working group, advance project on PoC / EVT / DVT / PVT cadence

We aim to identify our partner during 2026, and jointly launch PoC work in the second half of 2026. This cadence positions Restora to capitalize on the 2026–2027 industry window and become the first-mover in orthopedic rehabilitation neuromodulation.